VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today announced that it has finalized the selection criteria for the head and neck cancer target population to be treated with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback